stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Return on assets
Denali Therapeutics Inc.'s return on assets over the twelve months to 30 September 2026 was −27.2%, up 13.5 percentage points from fiscal 2025 (−40.7%). Over the past ten years it has ranged from −56.3% (fiscal 2016) to 6.59% (fiscal 2020); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −40.7% | (7.24) |
| FY2024 | −33.5% | (22.34) |
| FY2023 | −11.1% | 11.65 |
| FY2022 | −22.8% | (3.44) |
| FY2021 | −19.3% | (25.91) |
| FY2020 | 6.59% | 39.11 |
| FY2019 | −32.5% | (26.21) |
| FY2018 | −6.31% | 16.96 |
| FY2017 | −23.3% | 33.04 |
| FY2016 | −56.3% | (45.40) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. | −27.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement